GSK_Annual_Report_2021

Notes to the Consolidated Financial Statements for the year ended March 31, 2021 (contd.) Financial Statements GlaxoSmithKline Pharmaceuticals Limited 222 ( ` in lakhs) As at March 31, 2020 (n) Outstanding payables at the period end : GlaxoSmithKline South Africa (Pty) Ltd., South Africa 77.24 GlaxoSmithKline Biologicals S.A., Belgium 37,61.90 GlaxoSmithKline Export Limited, U.K. 14,89.10 Stiefel India Private Limited, India 23.03 GlaxoSmithKline Services Unlimited, U.K. 78.11 GlaxoSmithKline Asia Private Limited, India 1,97.53 SmithKline Beecham Limited, U.K. 13.73 ( ` in lakhs) As at March 31, 2020 (o) Cross charges recoverable at the period end : GlaxoSmithKline Biologicals S.A., Belgium 30.41 GlaxoSmithKline Export Limited, U.K. 31.69 GlaxoSmithKline Research & Development Ltd., U.K. 21.57 GlaxoSmithKline Services Unlimited, U.K. 16.27 Glaxo Operations UK Limited, U.K. 19.65 GlaxoSmithKline Pharmaceutical Ltd., Sri Lanka 5.63 (iv) Details relating to persons referred to in item 1(iii) above: ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 1 Remuneration / commission / sitting fees 37,93.20 40,91.89 2 Payments under the long-term incentive plan 2,95.47 5,16.49 (v) Disclosure in respect of material transactions with persons referred to in item 1(iii) above: ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 (a) Remuneration / commission / sitting fees (Refer Note below): Mr. A. Vaidheesh - 9,47.67 Mr. S. Venkatesh 8,21.46 - Mr. A. Iyer 3,42.86 4,54.17 Mr. R. Krishnaswamy 5,01.22 2,60.48 Ms. P. Thakur 3,27.63 3,98.40 Ms. M. Priyam 1,24.19 4,13.37